Prevention of late-onset neonatal sepsis (LOS) in infants born very preterm (<32 weeks' gestation) is paramount because of its associated mortality and morbidity. Lactoferrin has antimicrobial properties and could be preventive. 1 Lactoferrin concentrations in human breastmilk vary little with gestational age and fall over time after birth; 2 they are lower in infant formulas.
3 Importantly, very preterm infants have low enteral intakes in the first days after birth, and this can persist for weeks. Consequently, infants born very preterm might benefit from supplemental lactoferrin to prevent LOS.
In a 2017 Cochrane review, 4 enteral lactoferrin was found not only to reduce the rate of any LOS (risk ratio [RR] 0·59, 95% CI 0·40-0·87; p=0·008; from six trials including 886 participants) but also of necrotising enterocolitis (0·40, 0·18-0·86; p=0·02; from four trials including 750 participants). Five randomised controlled trials (RCTs) assessed bovine lactoferrin and one tested human recombinant lactoferrin. However, the quality of all the included studies was low. The authors of the review made no recommendation to introduce bovine lactoferrin into clinical practice.
In The Lancet, the ELFIN Trial Investigators Group reports its large multicentre RCT, 5 which was designed to address the limitations of the existing evidence in the use of bovine lactoferrin to prevent LOS. They recruited 2203 infants born at less than 32 weeks' gestation and younger than 72 h from 37 sites around the UK in just under 3·5 years. Infants were randomly allocated to receive either bovine lactoferrin (150 mg/kg daily, once the infants were receiving at least 12 mL/kg per day enterally) or an equal volume of sucrose placebo until 34 weeks' gestation. Bovine lactoferrin had little effect on the primary endpoint of LOS (316 [29%] of 1093 infants in the lactoferrin group and 334 [31%] of 1089 in the control group developed LOS; adjusted RR 0·95, 95% CI 0·86-1·04; p=0·233). Importantly, lactoferrin had little effect on other clinically important outcomes including mortality (1·05, 0·66-1·68; p=0·782) and the combined outcome of mortality with LOS, necrotising enterocolitis, or bronchopulmonary dysplasia (1·01, 0·94-1·08; p=0·743).
The study design and governance appear exemplary. Infants were at equal risk of reaching the endpoint through randomisation, other clinical care was equal because of effective blinding, the primary clinically important outcome of LOS was known for all but 1% (n=23) of those enrolled, the infants were representative of very preterm infants in high-income countries, and treatment compliance was excellent. Moreover, they reported other clinically important outcomes including mortality, necrotising enterocolitis, bronchopulmonary dysplasia, and retinopathy of prematurity, and the combined outcome of death with any LOS, necrotising enterocolitis, bronchopulmonary dysplasia, or retinopathy of pre maturity. The study progressed on schedule, with the appropriate surveillance of safety, and the results have been reported promptly. Although the intent was to apply for funding for later neurodevelopmental follow-up of survivors, the investigators argued that the absence of an effect on the primary outcome meant that bovine lactoferrin was unlikely to be introduced clinically and that follow-up was not required. Acquiring funding for follow-up would also be challenging in the absence of any clear short-term effects of bovine lactoferrin. What do these results mean for clinical practice? Combining the results of the ELFIN trial 5 with those already in the Cochrane review 4 in a standard metaanalysis, the effect of bovine lactoferrin on LOS becomes marginal (RR 0·89, 95% CI 0·79-1·00; p=0·06), and the effect on necrotising enterocolitis almost disappears (0·92, 0·67-1·26; p=0·60). However, combining an excellent quality, large RCT with multiple smaller RCTS of low quality is suboptimal to justify clinical care. The ELFIN investigators are planning a meta-analysis, presumably of individual participant data, with other trials, some of which are large and unreported, which will provide more robust evidence to help guide clinical care, so the final verdict might take a while yet.
The role of bovine lactoferrin in more mature infants or in low-income or middle-income countries is unclear. Neonatal sepsis is common and is an important cause of mortality in neonatal units in low-income and middle-income countries. 6, 7 A small RCT was positive in reducing sepsis, but most cases occurred after discharge home, suggesting different mechanisms for sepsis in some low-income or middleincome settings. 8 For now, it would be unwise to use bovine lactoferrin in clinical practice, or to embark on new RCTs of bovine lactoferrin to reduce LOS in very preterm infants in high-income countries. As indicated by the ELFIN investigators, future research to reduce LOS and necrotising entero colitis in very preterm infants should look beyond bovine lactoferrin supplementation. New therapeutic options to prevent LOS seem unlikely. Attempts at passive immune therapy with bovine lactoferrin 5 or monoclonal anti-staphylococcal antibodies 9 have not been convincing. The balance of evidence does not favour routine prevention with antimicrobials. 10 Although probiotics do not reduce LOS, they do reduce necrotising enterocolitis and mortality, 11 and are being introduced into clinical practice. 12 There is good evidence for hand hygiene as part of a package of care designed to reduce LOS. 13 The key to reducing LOS is likely to be in decreasing the number and duration of procedures, such as assisted breathing technologies and parenteral nutrition, that involve foreign bodies, which are potential conduits for the low virulence culprits of LOS. Dietary carbohydrates are a diverse group of molecules that range from simple sugars to highly complex polysaccharides, such as starch and dietary fibre. The importance of carbohydrates in human nutrition cannot be underestimated; they are the principal energy source in most societies throughout the world. Carbohydrate is often viewed as a health-neutral energy filler, used to make up the energy content of the diet in place of dietary fat. This replacement of dietary fat is in response to public health guidance on avoiding coronary heart disease. However, the impact carbohydrate can have on human health is exemplified by the relationship between sucrose consumption and dental health, and more recently the contribution of sugar sweetened beverages to excessive dietary energy intake resulting in weight gain and obesity. This finding has led to WHO recommendations to reduce sucrose intake to less than 10% of total energy intake, 1, 2 and resulted in various public health policies, including increased taxation on high-sugar food and drink.
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Relatively little attention has been paid to the health outcomes associated with other types of dietary carbohydrate. The WHO-commissioned research reported by Andrew Reynolds and colleagues 4 in The Lancet bridges this gap. Here, the authors use systematic review and meta-analysis methodology to bring together prospective cohort and randomised controlled trials, which reported on indicators of carbohydrate quality and non-communicable disease incidence, mortality, and risk factors. The authors had a large dataset of 135 million person-years from prospective studies and 58 clinical trials with a total of 4635 adult participants for the analysis. From these data, the authors were able to show a 15-30% decrease in allcause and cardiovascular-related mortality, and incidence of coronary heart disease, stroke, type 2 diabetes, and colorectal cancer when comparing the highest dietary fibre consumers with the lowest from the prospective cohort data. These observations were supported by the findings from risk factor measurements in the clinical trial evidence, which showed a significantly lower bodyweight, systolic blood pressure, and total cholesterol when comparing higher with lower intakes of dietary fibre. Similar observations were made with whole grain intake. However, the impact of glycaemic index on these outcomes was less clear.
The authors focus on the relationship between carbohydrate quality and non-communicable disease incidence, mortality, and risk factors. 4 Carbohydrate quality was measured by intakes of dietary fibre, whole grains, or pulses, and dietary glycaemic index or glycaemic load. It is important to recognise that these indicators of carbohydrate quality are not defined by the chemical make-up of the carbohydrate alone, but comprise of broad groups of molecules and food structures.
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